Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Unilever plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.01 (market cap $29.60B), while Unilever plc trades at $61.59 (market cap $134.06B). The key difference: Unilever plc is far larger — about 4.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Unilever plc pays a 3.65% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | UL | |
|---|---|---|
Market Cap | $29.60B | $134.06B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $74.59 |
52-Week Low | $205.48 | $55.05 |
Enterprise Value | $27.56B | $159.86B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Unilever (UL) trades at $62.86, down 0.16% on the day, with a bearish technical signal. The stock shows strong profitability with a net income margin of 18.75% and ROE of 53.32%, though recent quarters have seen EPS misses. Revenue declined to $50.50B in 2025, but cash flow from operations remains robust at $8.35B. News highlights include a planned $65 billion merger with McCormick's food business and strong Q2 2026 volume growth, prompting an upgraded outlook.
The outlook is mixed: valuation ratios like P/E of 20.84 are reasonable, and the merger could drive growth, but consistent earnings misses and a high P/B of 7.49 pose risks. Analyst sentiment is neutral with 51.36% hold ratings. Investors should weigh the transformative deal potential against execution risks and margin pressures in a volatile consumer goods market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
